Test subject No: H0008
Date of report: 08/12/2021
Name: Lea NLN (Axel NLN)
DOB: 09/10/2001
Gender: M
Status report: Subject responded well to exposure to Formula 11 applied topically to the cervical dermis at 305K. Immediate favourable mutation observed at genetic level across entire body in a pattern similar to H0007. Formula 07 was administered intravenously to halt the mutation. H0008 shows promise. With results almost identical to H0007 it appears that we have finally reached the consistency required to initiate testing drug naïve individuals.
I recommend immediately authorising use of F07 and F11 on H0009, H0010, H0011 and H0012. Caution should be exercised with H0012, liberal use of diacetylmorphine and F09 should keep her safe for the duration of the test.
In the case of H0008 I recommend an immediate course of F03 and F07. H0008 is to be considered an active member of The Organization starting immediately and shall report directly to me.
Xemnas (No.I)
p.s. I have found a base model for H0013, a tissue sample should be collected from him when he visits the labs on 08/17/2021. H0013 is to be the final subject before we roll out into mass production. As such, it is of paramount importance that the sample is uncontaminated and carefully screened before cloning. F13 should be used in the tests as F12 is still too unpredictable. Maintain reserves of F12 in Delta Block at low security. (It would be a shame if this 'Ventus' was exposed to the formula too early; we wouldn't want another Subject Zero on our hands.)
p.p.s. reserve number H0014 for immediate use.